Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Tamura A"'
Autor:
Akira Saito, Hideyuki Ohzawa, Yuki Kaneko, Kohei Tamura, Yurie Futoh, Kazuya Takahashi, Yuki Kimura, Rie Kawashima, Hideyo Miyato, Joji Kitayama, Naohiro Sata
Publikováno v:
Cancer Research. 83:1268-1268
Background: Although metformin (Met) is well known to suppress tumor growth, the detailed mechanisms of its anti-tumor effect remain unknown. In recent years, it has been pointed out that tumor-associated neutrophils (TAN) can produce neutrophil extr
Autor:
Kohei Tamura, Hideyo Miyato, Misaki Matsumiya, Rei Takahashi, Yuki Kaneko, Yurie Futoh, Kazuya Takahashi, Yuki Kimura, Akira Saito, Hideyuki Ohzawa, Yasushi Saga, Yuji Takei, Hiroyuki Fujiwara, Joji Kitayama
Publikováno v:
Cancer Research. 83:2266-2266
Objective: High density of tumor-infiltrating lymphocytes (TIL) in the tumor is associated with favorable prognosis of cancer patients. It has been reported that many neutrophils also infiltrate in various tumor tissues as tumor-associated neutrophil
Autor:
Shun Kawaguchi, Nobuko Tamura, Kiyo Tanaka, Yoko Kobayashi, Junichiro Sato, Keiichi Kinowaki, Masato Shiiba, Makiko Ishihara, Hidetaka Kawabata
Publikováno v:
Cancer Research. 83:P5-01
Background: Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) are useful imaging modalities for the preoperative nodal staging in breast cancer; however, clinical evidence demonstrating the diagnostic accu
Autor:
Lin Zhang, Yali Liu, Shanu Modi, Sara A. Hurvitz, Yeon Hee Park, Javad Shahidi, Cristina Saura, Junji Tsurutani, Seock-Ah Im, Hiroji Iwata, Yoshinori Ito, Ian E. Krop, Keun Seok Lee, Neelima Denduluri, Kenji Tamura, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Caleb Lee, José Baselga, Christophe Perrin, Sung Bae Kim, Kenjiro Aogi, Fabrice Andre, Javier Cortes, Antoine Yver
Publikováno v:
Cancer Research. 81:PD3-06
Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) is an open-label, international,
Autor:
Taira Naruto, Satoshi Morita, Koichiro Tsugawa, Masato Takahashi, Hiroji Iwata, Yoshie Hasegawa, Masakazu Toi, Tetsuhiro Yoshinami, Shigehira Saji, Norikazu Masuda, Hiroshi Tada, Kenji Tamura, Takashi Yamanaka, Takayuki Ueno, Fumikata Hara, Shinji Ohno, Yutaka Yamamoto, Toshimi Takano, Tatsuya Toyama, Masahiro Kashiwaba
Publikováno v:
Cancer Research. 81:PD3-11
Background: Patients (pts) with HER2-positive locallyadvanced/metastatic breast cancer (LA/MBC) previously treated with pertuzumab(P)-containing regimens have few therapeutic options. The efficacy of Pre-treatment combined with trastuzumab (T)+chemot
Autor:
Catherine M. Green, Frances R. Balkwill, Jun Wang, Daniela Moralli, Tanya N. Soliman, Sarah E. McClelland, Nadeem Shaikh, Jennifer R. McGuinness, Mary-Anne Durin, Daniel Muliaditan, Eleni Maniati, Naoka Tamura, Kit Curtius
Publikováno v:
Cancer Research. 80:4946-4959
Chromosomal instability (CIN) comprises continual gain and loss of chromosomes or parts of chromosomes and occurs in the majority of cancers, often conferring poor prognosis. Because of a scarcity of functional studies and poor understanding of how g
Autor:
Yuki Kimura, Hideyuki Ohzawa, Yuki Kaneko, Kohei Tamura, Yurie Futoh, Kazuya Takahashi, Akira Saito, Mineyuki Tojo, Hideyo Miyato, Joji Kitayama
Publikováno v:
Cancer Research. 82:6284-6284
Background: Mesothelial cells play tumor-promoting roles in the development of peritoneal metastasis (PM) through mesothelial-mesenchymal transition (MMT). We reported miR-29b suppressed MMT of human peritoneal mesothelial cell (HPMC). Methods: MiR-2
Autor:
Akira Saito, Hideyuki Ohzawa, Yuki Kaneko, Kohei Tamura, Yurie Futoh, Kazuya Takahashi, Yuki Kimura, Mineyuki Tojo, Rie Kawashima, Hideyo Miyato, Naohiro Sata, Joji Kitayama
Publikováno v:
Cancer Research. 82:6379-6379
Background: Type2 diabetes mellitus(T2DM) is a risk factor for cancer. Recent studies have shown that DPP-4 inhibitor(DPP-4i) can either promote or suppress cancer progression. However, the detailed mechanisms remain unknown. Here, in this study, we
Autor:
Yuki Kaneko, HIdeyuki Ohzawa, Yuki Kimura, Kohei Tamura, Yurie Futoh, Kazuya Takahashi, Akira Saito, Mineyuki Tojo, Hideyo Miyato, Naohiro Sata, Joji Kitayama
Publikováno v:
Cancer Research. 82:6285-6285
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and an inherently chemoresistant tumor. Dense fibrotic stroma is a major obstacle for drug delivery to the tumor cells in PDAC. Pancreatic stellate cells (PSCs
Autor:
Hiroji Iwata, Aditya Bardia, Simon Lord, Hannah M. Linden, Mario Campone, Kenji Tamura, Kan Yonemori, Toru Mukohara, Cécile Combeau, Nils Ternes, Dimitri Carene, Jeff Ming, Joon Sang Lee, Marina Celanovic, Anne-Laure Bauchet, Monsif Bouaboula, Tomoyuki Tanaka, Yumiko Kawabata, Sarat Chandarlapaty
Publikováno v:
Cancer Research. 82:CT517-CT517
Background: Amcenestrant is an optimized oral SERD that has shown safety and clinical benefit in patients (pts) with wild-type (WT) and mutated ESR1 aBC. Here we provide a pooled analysis of biomarkers from two studies in heavily-pretreated, postmeno